Fulltext present in this item

Thumbnail
Fulltext: 196133.pdf
Format: PDF
Description: publisher's version
Embargo: until further notice
Title: Pharmacokinetics, Short-term Safety and Efficacy of the Approved Once-daily Darunavir/Ritonavir Dosing Regimen in HIV-infected Children
Author(s): Bastiaans, D.E.T. ; Geelen, S.P.; Visser, E.G.; Flier, M. van der ; Vermont, C.L.; Colbers, A.P. ; Roukens, M.M. ; Burger, D.M. ; Rossum, A.M. van
Publication year: 2018
Source: Pediatric Infectious Disease Journal, vol. 37, iss. 10, (2018), pp. 1008-1010
ISSN: 0891-3668
DOI: https://doi.org/10.1097/INF.0000000000001964
Publication type: Article / Letter to editor

Please use this identifier to cite or link to this item : https://hdl.handle.net/2066/196133   https://hdl.handle.net/2066/196133

Display more details
Subject: Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
Radboudumc 4: lnfectious Diseases and Global Health RIMLS: Radboud Institute for Molecular Life Sciences
Organization: Clinical Pharmacy
Paediatrics
Laboratory Medicine
Journal title:
Pediatric Infectious Disease Journal
Volume: vol. 37
Issue: iss. 10
Page start: p. 1008
Page end: p. 1010
Abstract:
In this multicenter pharmacokinetic study in HIV-infected children (6-12 years of age), we validated the approved once-daily darunavir/ritonavir dosing recommendations. The geometric mean darunavir area under the plasma concentration-time curve was 63.1 h.mg/L, substantially lower than the mean value observed in adults. However, all trough levels were adequate, and short-term virologic outcome was good. These data support the use of the darunavir/ritonavir once-daily dosing recommendations.

This item appears in the following Collection(s)

Browse

Statistics